Authors' objectives: Neovascular, or 'wet' age-related macular degeneration (AMD), is a painless eye condition that causes loss of central vision, usually in both eyes. The sight loss usually happens gradually over time, although it can sometimes be rapid. Wet AMD occurs when abnormal blood vessels grow in the middle part of the retina at the back of the eye (called the macular). It is the most common cause of vision loss in people aged over 60. Pegpleranib is a new drug to treat wet AMD. It is given as an injection directly into the eye, along with one of a number of other drugs which are already regularly used for this disease. Pegpleranib is currently being studied to see how well it works and whether it is safe to use in people with wet AMD. If pegpleranib is licensed for use in the UK, it will offer a new treatment for people with wet AMD.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/pegpleranib-fovista-for-neovascular-age-related-macular-degeneration/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)